The study analyzed 101 mpox cases from 13 countries reported last year to the American Academy of Dermatology/International League of Dermatologic Societies registry.
Registry data indicate that cutaneous reactions to the COVID-19 vaccine do not predict an increased risk of a serious reaction, cutaneous or otherwise, to either a second dose or booster.